Bethan Psaila

Bethan Psaila is a physician-scientist known for work in hematopoiesis, megakaryocyte/platelet biology and myeloproliferative neoplasms (MPNs). She is Professor of Hematology at the University of Oxford, a Cancer Research UK funded Senior Fellow, and a Senior Fellow of New College. In 2021, she co-founded Alethiomics, a drug-discovery company.

Education

Psaila received her undergraduate and medical training at Clare College, Cambridge and University College London Hospitals. She went on to pursue a PhD degree at Imperial College London and Weill-Cornell University Medical School in New York, where she studied the role of megakaryocytes in cancer metastasis. She completed her specialty training in hematology at the Hammersmith Hospital as an NIHR Academic Clinical Lecturer at Imperial College London. Psaila was granted a prestigious Wellcome Clinical Career Development Fellowship, which supported further postdoctoral research in David Bodine's laboratory at the National Human Genome Research Institute in Maryland and with Professors Adam Mead and Irene Roberts at the MRC Weatherall Institute of Molecular Medicine, University of Oxford. She then obtained a Cancer Research UK Advanced Clinician Scientist to establish her own laboratory in the MRC WIMM in August 2019.

Research

Psaila is Professor of Hematology at the University of Oxford and serves as a Group Leader at the MRC Weatherall Institute of Molecular Medicine and Associate Member of the Oxford Ludwig Institute for Cancer Research. Her research focuses on the tumor microenvironment in blood cancers:

Interactions in normal and malignant hematopoiesis – Investigating the interactions between blood stem cells, megakaryocytes, and the stroma in both normal and malignant hematopoiesis.